A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosisSriram Ravichandran, Ashutosh Wechalekar, Julian D. Gillmore et al.|Amyloid|2023Cited by 9
A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial ResultsMamta Garg, Ashutosh Wechalekar, Andrew Hall et al.|Blood|2019Cited by 5
Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine TrialMatthew Jenner, Martin Kaiser, Andrew Hall et al.|Blood|2021Cited by 2